Optimization of base editors for the functional correction of SMN2 as a treatment for spinal muscular atrophy

被引:7
|
作者
Alves, Christiano R. R. [1 ,2 ,3 ]
Ha, Leillani L. [1 ,4 ]
Yaworski, Rebecca [5 ,6 ,7 ]
Sutton, Emma R. [5 ,6 ,7 ]
Lazzarotto, Cicera R. [8 ]
Christie, Kathleen A. [1 ,4 ,9 ]
Reilly, Aoife [5 ,6 ,7 ]
Beauvais, Ariane [5 ,6 ,7 ]
Doll, Roman M. [1 ,4 ,10 ,11 ]
de la Cruz, Demitri [12 ,13 ]
Maguire, Casey A. [12 ,13 ]
Swoboda, Kathryn J. [1 ,2 ,3 ]
Tsai, Shengdar Q. [8 ]
Kothary, Rashmi [5 ,6 ,7 ,14 ]
Kleinstiver, Benjamin P. [1 ,4 ,9 ]
机构
[1] Massachusetts Gen Hosp, Ctr Genom Med, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA
[3] Harvard Med Sch, Dept Neurol, Boston, MA 02115 USA
[4] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA
[5] Ottawa Hosp Res Inst, Ottawa, ON, Canada
[6] Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON, Canada
[7] Univ Ottawa, Ctr Neuromuscular Dis, Ottawa, ON, Canada
[8] St Jude Childrens Res Hosp, Dept Hematol, Memphis, TN USA
[9] Harvard Med Sch, Dept Pathol, Boston, MA 02115 USA
[10] Heidelberg Univ, Mol Biosci Canc Biol Program, Heidelberg, Germany
[11] German Canc Res Ctr, Heidelberg, Germany
[12] Massachusetts Gen Hosp, Dept Neurol, Mol Neurogenet Unit, Charlestown, MA USA
[13] Harvard Med Sch, Program Neurosci, Boston, MA USA
[14] Univ Ottawa, Dept Med, Ottawa, ON, Canada
基金
加拿大健康研究院; 美国国家卫生研究院;
关键词
SURVIVAL MOTOR-NEURON; CRISPR-CAS9; NUCLEASES; SPLICING MODIFIER; NATURAL-HISTORY; SHAM CONTROL; GENOMIC DNA; MOUSE MODEL; NUSINERSEN; RISDIPLAM; THERAPY;
D O I
10.1038/s41551-023-01132-z
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Spinal muscular atrophy (SMA) is caused by mutations in SMN1. SMN2 is a paralogous gene with a C center dot G-to-T center dot A transition in exon 7, which causes this exon to be skipped in most SMN2 transcripts, and results in low levels of the protein survival motor neuron (SMN). Here we show, in fibroblasts derived from patients with SMA and in a mouse model of SMA that, irrespective of the mutations in SMN1, adenosine base editors can be optimized to target the SMN2 exon-7 mutation or nearby regulatory elements to restore the normal expression of SMN. After optimizing and testing more than 100 guide RNAs and base editors, and leveraging Cas9 variants with high editing fidelity that are tolerant of different protospacer-adjacent motifs, we achieved the reversion of the exon-7 mutation via an A center dot T-to-G center dot C edit in up to 99% of fibroblasts, with concomitant increases in the levels of the SMN2 exon-7 transcript and of SMN. Targeting the SMN2 exon-7 mutation via base editing or other CRISPR-based methods may provide long-lasting outcomes to patients with SMA.
引用
收藏
页码:118 / +
页数:17
相关论文
共 50 条
  • [1] Risdiplam SMN2 splicing modulator Treatment of spinal muscular atrophy
    Chiriboga, C. A.
    DRUGS OF THE FUTURE, 2019, 44 (08) : 643 - 658
  • [2] High Concentration or Combined Treatment of Antisense Oligonucleotides for Spinal Muscular Atrophy Perturbed SMN2 Splicing in Patient Fibroblasts
    Wijaya, Yogik Onky Silvana
    Niba, Emma Tabe Eko
    Nishio, Hisahide
    Okamoto, Kentaro
    Awano, Hiroyuki
    Saito, Toshio
    Takeshima, Yasuhiro
    Shinohara, Masakazu
    GENES, 2022, 13 (04)
  • [3] Tetracyclines That Promote SMN2 Exon 7 Splicing as Therapeutics for Spinal Muscular Atrophy
    Hastings, Michelle L.
    Berniac, Joel
    Liu, Ying Hsiu
    Abato, Paul
    Jodelka, Francine M.
    Barthel, Lea
    Kumar, Sujatha
    Dudley, Caroline
    Nelson, Mark
    Larson, Kelley
    Edmonds, Jason
    Bowser, Todd
    Draper, Michael
    Higgins, Paul
    Krainer, Adrian R.
    SCIENCE TRANSLATIONAL MEDICINE, 2009, 1 (05)
  • [4] Antisense oligonucleotides targeting the SMN2 promoter region enhance SMN2 expression in spinal muscular atrophy cell lines and mouse model
    Wang, Jia
    Bai, Jinli
    OuYang, Shijia
    Wang, Hong
    Jin, Yuwei
    Peng, Xiaoyin
    Ge, Xiushan
    Jiao, Hui
    Zou, Jizhen
    He, Cai
    Xiao, Ping
    Song, Fang
    Qu, Yujin
    HUMAN MOLECULAR GENETICS, 2022, 31 (10) : 1635 - 1650
  • [5] Combined treatment with the histone deacetylase inhibitor LBH589 and a splice-switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in Spinal Muscular Atrophy cells
    Pagliarini, Vittoria
    Guerra, Marika
    Di Rosa, Valentina
    Compagnucci, Claudia
    Sette, Claudio
    JOURNAL OF NEUROCHEMISTRY, 2020, 153 (02) : 264 - 275
  • [6] Patient-specific responses to SMN2 splice-modifying treatments in spinal muscular atrophy fibroblasts
    Signoria, Ilaria
    Zwartkruis, Maria M.
    Geerlofs, Lotte
    Perenthaler, Elena
    Faller, Kiterie M. E.
    James, Rachel
    McHale-Owen, Harriet
    Green, Jared W.
    Kortooms, Joris
    Snellen, Sophie H.
    Asselman, Fay-Lynn
    Gillingwater, Thomas H.
    Viero, Gabriella
    Wadman, Renske I.
    van der Pol, W. Ludo
    Groen, Ewout J. N.
    MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT, 2024, 32 (04)
  • [7] Bone loss in survival motor neuron (Smn-/- SMN2) genetic mouse model of spinal muscular atrophy
    Shanmugarajan, Srinivasan
    Tsuruga, Eichi
    Swoboda, Kathryn J.
    Maria, Bernard L.
    Ries, William L.
    Reddy, Sakamuri V.
    JOURNAL OF PATHOLOGY, 2009, 219 (01): : 52 - 60
  • [8] Restoring SMN Expression: An Overview of the Therapeutic Developments for the Treatment of Spinal Muscular Atrophy
    Aslesh, Tejal
    Yokota, Toshifumi
    CELLS, 2022, 11 (03)
  • [9] SAM68 is a physiological regulator of SMN2 splicing in spinal muscular atrophy
    Pagliarini, Vittoria
    Pelosi, Laura
    Bustamante, Maria Blaire
    Nobili, Annalisa
    Berardinelli, Maria Grazia
    D'Amelio, Marcello
    Musaro, Antonio
    Sette, Claudio
    JOURNAL OF CELL BIOLOGY, 2015, 211 (01): : 77 - 90
  • [10] Risdiplam: an investigational survival motor neuron 2 (SMN2) splicing modifier for spinal muscular atrophy (SMA)
    Markati, Theodora
    Fisher, Gemma
    Ramdas, Sithara
    Servais, Laurent
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2022, 31 (05) : 451 - 461